EGFR NSCLC Generic Drug Tablets

Dacomitinib is a therapy specifically designed for non-small cell lung cancer. It works by targeting the EGFR in cancer cells when they have these specific gene changes—either exon 19 is deleted or there’s an L858R mutation in exon 21. This drug belongs to a group called tyrosine kinase inhibitors.

It stops the growth of cancer cells by blocking EGFR signaling. Dacomitinib comes in tablet form with three doses to choose from: 15, 30, and 45 mg. The suggested amount you should take is 45 mg, taken just once each day.

Each dose size comes in a bottle with 30 of those tablets.